Board of Directors
James Green is Chairman, President and Chief Executive Officer of Harvard Bioscience. He was named President and Chief Executive Officer in July 2019 and Chairman of the Board of Directors in June 2017. Green has been a member of the Company’s Board of Directors since April 2015. Green served as President and Chief Executive Officer of Analogic Corporation (NASDAQ: ALOG) from 2007 to 2016. While leading the public company through the great recession, Analogic’s core revenues grew over 50%, and gross margins, operating margins and earnings per share dramatically improved. Immediately prior to becoming President and Chief Executive Officer of Harvard Bioscience, Green served as President of Spacelabs Healthcare, where he led a successful global restructuring, rationalizing the company’s cost structure and product portfolio and quickly stabilized revenues while significantly improving operating margins. Earlier in his career, Green was Regional Vice President of a division of Quest Diagnostics Corporation, Sr. VP & General Manager of Koninklijke Philips Electronics NV Global Computed Tomography Business and held various leadership positions at St. Jude Medical Inc., Beckman Instruments, McDonnell Douglas Corporation and Northrop Advanced Systems. Green earned a bachelor’s degree in electrical engineering from the University of Missouri at Columbia and a master’s degree in computer engineering from the University of Southern California and is a graduate of the Stanford University Executive Program.
Katherine Eade was appointed a Director of the Company on October 24, 2017, and is Chair of the Governance Committee and a member of the Audit Committee. Ms. Eade is General Counsel of Checkmate Pharmaceuticals and has more than 19 years of experience advising public companies on M&A and other significant corporate transactions, corporate governance and capital markets, including a dozen years in the life science industry. Ms. Eade began her legal career as an attorney at Cleary Gottlieb, a leading international law firm, where she worked for over seven years, and she also served as a law clerk for Judge Morton I. Greenberg of the U.S. Court of Appeals for the Third Circuit. Ms. Eade earned a J.D., cum laude, from Harvard Law School and a B.A. in Government, summa cum laude, from Cornell University. We believe Ms. Eade’s qualifications to sit on our Board of Directors include her significant experience in mergers and acquisitions in the life sciences industry and her extensive experience in capital markets and corporate governance.
Alan Edrick was appointed a Director of the Company on September 3, 2019 and is Chair of the Audit Committee and a member of the Compensation Committee. Mr. Edrick has over 25 years of financial management and public accounting experience, including mergers and acquisitions, capital markets, financial planning and analysis, and regulatory compliance. Mr. Edrick joined OSI Systems, Inc., in September 2006 as Executive Vice President and Chief Financial Officer. Between 2004 and 2006, he served as Executive Vice President and Chief Financial Officer of BioSource International, Inc. until its sale to Invitrogen Corporation. Between 1998 and 2004, Mr. Edrick served as Senior Vice President and Chief Financial Officer of North American Scientific, Inc., a medical device and specialty pharmaceutical company. Between 1989 and 1998, he was employed by Price Waterhouse LLP in various positions including Senior Manager, Capital Markets. Mr. Edrick received his Bachelor of Arts degree from the University of California, Los Angeles and a Master of Business Administration degree from the Anderson School at the University of California, Los Angeles.
Thomas Loewald was appointed a Director of the Company on October 24, 2017 and is Chair of the Compensation Committee and a member of the Governance Committee and the Audit Committee. In September, 2020, Mr. Loewald joined Cambrex, a leading private equity-owned Contract Development & Manufacturing Organization, as President and CEO.
Previously, Mr. Loewald served as President of the Flexibles Division of ProAmpac, a leading flexible packaging manufacturer. Prior to ProAmpac, he served as Senior Vice President and Chief Commercial Officer at Thermo Fisher Scientific, a recognized world leader in serving science and a highly effective industry consolidator, as well as Group President of the $1.6 B Laboratory Products Group. In his role as CCO, he was responsible for designing and leading Thermo Fisher’s commercial strategy and enterprise-spanning commercial resources. During a 14-year tenure with Thermo Fisher, Mr. Loewald played a key role in helping the company expand from a $3 B to a $20 B company. He had also served as the SVP and President of the company’s $3.7 B Analytical Instruments Group, held two Division President roles and was VP of Sales and Services for the Environmental Instruments Division. Earlier in his career, Mr. Loewald led sales, marketing, and customer service for the $400 MM adhesives division of Tyco International. Prior to Tyco, he held a series of roles with General Electric’s Plastics and Materials businesses.
Mr. Loewald graduated cum laude from Middlebury College, majoring in Economics, and received an MBA from the Amos Tuck School at Dartmouth College. We believe his qualifications to sit on our Board of Directors include his broad global business experience in a wide range of industries from commodity to high growth, his strong strategic management and leadership skills, and his extensive record of success in leading business growth and excellence.
Bertrand Loy was appointed Director of the Company on November 6, 2014. Mr. Loy was appointed Lead Independent Director and is a member of the Compensation Committee and the Governance Committee. Mr. Loy is President and CEO of Entegris Inc., a provider of yield-enhancing materials and solutions used in advanced high-tech manufacturing environments. He earlier served as Chief Operating Officer and Chief Administrative Officer of Entegris; under his leadership he helped grow the company's revenue to $1.1 billion. He previously worked as Chief Financial Officer of Mykrolis Corp., the former microelectronics division of Millipore. Prior to this, he was with Millipore initially as the Director of Finance and Manufacturing for Millipore's Laboratory Water Division before moving to the position of Chief Information Officer. He began his career with Sandoz Pharmaceuticals (now Novartis) where he held various positions in strategic planning and finance in Europe, Japan and Latin America. Mr. Loy earned an MBA at ESSEC Business School in France.